Showing results (1341-1350 of 1,512) with videos related to

Sort By:
Pageof 152
European Journal of Epidemiology|October 23, 2008
Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES studyM Dramé, J L Novella, P O Lang, et al.
Journal of the American Society of Nephrology : JASN|February 11, 2014
Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathyJay C Jha, Stephen P Gray, David Barit, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|June 22, 2011
[Frailty: learnings from the SAFEs cohort study and future perspectives for the research]Pierre-Olivier Lang, Moustapha Dramé, Rachid Mahmoudi, et al.
Archives of Cardiovascular Diseases|January 27, 2020
Transcatheter closure of a perimembranous ventricular septal defect with Nit-Occlud Lê VSD Coil: A French multicentre studyAli Houeijeh, François Godart, Zakaria Jalal, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|September 9, 2018
Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activityOsama Saher, Cristina S J Rocha, Eman M Zaghloul, et al.
Nature Communications|October 9, 2023
A human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes modelsFabian Wirth, Fabrice D Heitz, Christine Seeger, et al.
Archives of Gynecology and Obstetrics|September 20, 2022
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT databaseM Bossart, H Plett, B Krämer, et al.
Revue D'Epidemiologie Et De Sante Publique|May 22, 2012
Six-month outcome of elderly people hospitalized via the emergency department: the SAFES cohortM Dramé, P O Lang, J-L Novella, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Cancers|January 11, 2022
Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment MonitoringElena Ioana Braicu, Andreas du Bois, Jalid Sehouli, et al.
Pageof 152